Rob Lin, PhD

CEO Avista Therapeutics

Rob Lin, PhD, CFA, is CEO of Avista Therapeutics, a UPMC incubated company focused on ophthalmology gene therapy products. Prior to Avista, Dr. Lin was vice president of Translational Sciences at UPMC Enterprises. He also was the Founding CEO of BlueSphere Bio, another UPMC incubated company. Prior to working at UPMC, Dr. Lin led the finance and strategy team for the Global Health Program at the Bill & Melinda Gates Foundation. His previous experiences also include stints at Millennium Pharmaceuticals (now Takeda Oncology) and Dean and Company as a strategy consultant. Dr. Lin earned a PhD in Genetics and an MMSc at Harvard University, as well as an MS in Chemical Engineering and a BS in Biological Sciences from Stanford University. He is a CFA Charterholder and previous Term Member of the Council on Foreign Relations (CFR).

Our website uses cookies, including third parties’ profiling cookies, to improve the functionality of the site and your user experience. You can learn more about how we use cookies and how to change your cookies settings in our Privacy Policy. By closing this message, clicking below or continuing to use this site, you consent to our use of cookies.